

CLEAN LISTING OF THE CLAIMS:

74. (Previously Presented) A method of downregulating the inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by introducing follistatin into said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

75. (Previously Presented) A method of therapeutically treating a condition characterized by an aberrant, unwanted or otherwise inappropriate inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by administering follistatin to said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

76. (Previously Presented) A method of downregulating the inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by introducing follistatin isoform 288 or follistatin isoform 315 into said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

77. (Previously Presented) A method of therapeutically treating a condition characterized by an aberrant, unwanted or otherwise inappropriate inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by administering follistatin isoform 288 or follistatin isoform 315 to said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

78. (Amended herein) A method of downregulating the inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by introducing follistatin into said mammal, and wherein the

inflammatory response occurs in the context of aberrant, unwanted or otherwise inappropriate acute inflammation of the airways.